Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1357884 | 0.91 | NPC1 (0.45) | HTTNPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL1357389 | 0.88 | NPC1 (0.48) | HTTNPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL1357842 | 0.81 | SMN1; SMN2 (0.47) | HTTNPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL1358601 | 0.81 | SMN1; SMN2 (0.46) | HTTNPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL12856882 | 0.81 | NPC1 (0.46) | HTTNPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL14733954 | 0.80 | NPC1 (0.53) | HTTNPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL26661473 | 0.80 | RAB9A (0.56) | HTTNPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL1357848 | 0.80 | SMN1; SMN2 (0.46) | HTTNPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL13840140 | 0.79 | RAB9A (0.52) | HTTNPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL4075702 | 0.79 | SMN1; SMN2 (0.54) | HTTNPC1RAB9ASMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859186-B2 | Polyimide precursor, resin composition comprising the polyimide precursor, pattern forming method using the resin composition, and articles produced by using the resin composition | DAI NIPPON PRINTING CO., LTD. (JP) | 2014-10-14 | — | — | US | disclosed |
| US-20110281218-A1 | POLYIMIDE PRECURSOR, RESIN COMPOSITION COMPRISING THE POLYIMIDE PRECURSOR, PATTERN FORMING METHOD USING THE RESIN COMPOSITION, AND ARTICLES PRODUCED BY USING THE RESIN COMPOSITION | DAI NIPPON PRINTING CO., LTD. (JP) | 2011-11-17 | — | — | US | disclosed |
| US-20090263745-A1 | POLYIMIDE PRECURSOR, RESIN COMPOSITION COMPRISING THE POLYIMIDE PRECURSOR, PATTERN FORMING METHOD USING THE RESIN COMPOSITION, AND ARTICLES PRODUCED BY USING THE RESIN COMPOSITION | DAI NIPPON PRINTING CO., LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263745-A1 | POLYIMIDE PRECURSOR, RESIN COMPOSITION COMPRISING THE POLYIMIDE PRECURSOR, PATTERN FORMING METHOD USING THE RESIN COMPOSITION, AND ARTICLES PRODUCED BY USING THE RESIN COMPOSITION | TERB1, PUF60, CD79B | HTT 2197/4885NPC1 4864/4885RAB9A 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.